key: cord-0260875-f06tz4kp authors: Alenquer, M.; Milheiro Silva, T.; Akpogheneta, O.; Ferreira, F.; Vale-Costa, S.; Medina-Lopes, M.; Batista, F.; Garcia, A. M.; Barreto, V. M.; Paulino, C.; Costa, J.; Sobral, J.; Diniz-da-Costa, M.; Ladeiro, S.; Delgado Alves, J.; Leite, R. B.; Demengeot, J.; Rocha Brito, M. J.; Amorim, M. J. title: Saliva molecular testing bypassing RNA extraction is suitable for monitoring and diagnosing SARS-CoV-2 infection in children date: 2021-08-12 journal: nan DOI: 10.1101/2021.08.11.21261899 sha: 1155a7d42b1921d6a84670dbfbeaff8d39f1f203 doc_id: 260875 cord_uid: f06tz4kp IMPORTANCE Adults are being vaccinated against SARS-CoV-2 worldwide, but the longitudinal protection of these vaccines is uncertain, given the ongoing appearance of SARS-CoV-2 variants. Children are susceptible to infection, and some studies reported that they actively transmit the virus even when asymptomatic, thus affecting the community. Methods to easily test infected children and track the virus they carry are in demand. OBJECTIVE To determine if saliva is an effective sample for detecting SARS-CoV-2 RNA and antibodies in children aged 10 years and under, and associate viral RNA levels to infectivity. DESIGN, SETTING, AND PARTICIPANTS In this cross-sectional study, saliva SARS-CoV-2 RT-qPCR tests, with and without RNA extraction, were validated in 49 hospitalized adults. The test was then applied to 85 children, aged 10 years and under, admitted to the hospital regardless of COVID-19 symptomatology. Amongst 85 children, 29 (63.0%) presented at least one COVID-19 symptom, 46 (54.1%) were positive for SARS-CoV-2 infection, 28 (32.9%) were under the age of 1 and the mean (SD) age was 3.8 (3.4) years. Saliva samples were collected up to 48 h after a positive test by nasopharyngeal (NP) swab-RT-qPCR. EXPOSURE Infection by SARS-COV-2 in adults up to 8 days post-symptom onset. Children admitted to hospital for any reason and therefore with unclear onset of SARS-CoV-2 infection. MAIN OUTCOMES AND MEASURES Saliva RT-qPCR up to CT<37 accurately identifies SARS-CoV-2 infected children, with viral infectivity in tissue culture restricted to CT<26. RESULTS In adults, the accuracy of the saliva SARS-CoV-2 RT-qPCR test was 98.0% (95% confidence intervals [CI]: 89.3%-100%) as compared to NP-RT-qPCR. In children, the sensitivity, specificity, and accuracy of saliva-RT-qPCR tests compared to NP swab-RT-qPCR were, respectively, 84.8% (71.8%-92.4%), 100% (91.0%-100%), and 91.8% (84.0%-96.6%) with RNA extraction and 81.8% (68.0%-90.5%), 100% (91.0%-100%), and 90.4% (82.1%-95.0%) without RNA extraction. The threshold for rescuing infectious particles from saliva was CT<26. There were significant IgM positive responses to the spike protein and its receptor-binding domain (RBD) among children positive for SARS-CoV-2 by NP swab and negative by saliva compared to other groups, indicating late infection onset (>7-10 days). CONCLUSIONS AND RELEVANCE Saliva-molecular testing is suitable in children aged 10 years and under, including infants aged <1 year, even bypassing RNA extraction methods. Importantly, the detected viral RNA levels were significantly above the infectivity threshold in several samples. Further investigation is required to understand how SARS-CoV-2 RNA levels correlate with viral transmission. Question: Is saliva reverse transcription-quantitative polymerase chain reaction (RT-qPCR) 24 testing (with and without RNA extraction) suitable to identify SARS-CoV-2 infected young 25 children and can the cycle threshold (CT) be associated with infectivity in a heterogeneous 26 population admitted to hospital for COVID-19-related and unrelated reasons? 27 Findings: In this cross-sectional study of 85 children aged 10 years and under, RT-qPCR in 28 saliva samples subjected or not to RNA extraction accurately detected SARS-CoV-2 RNA 29 and infectious viruses could be recovered from CTs below 26. 30 Meaning: Saliva sampling coupled to RT-qPCR and specific antibody detection efficiently 31 identifies infants and children infected with SARS-CoV-2. This approach is suitable for 32 surveillance in kindergarten and school settings. 4 qPCR were, respectively, 84.8% (71.8%-92.4%), 100% (91.0%-100%), and 91.8% (84.0%-60 96.6%) with RNA extraction and 81.8% (68.0%-90.5%), 100% (91.0%-100%), and 90.4% 61 (82.1%-95.0%) without RNA extraction. The threshold for rescuing infectious particles from 62 saliva was CT<26. There were significant IgM positive responses to the spike protein and its 63 receptor-binding domain (RBD) among children positive for SARS-CoV-2 by NP swab and 64 negative by saliva compared to other groups, indicating late infection onset (>7-10 days). 65 CONCLUSIONS AND RELEVANCE Saliva-molecular testing is suitable in children aged 66 10 years and under, including infants aged <1 year, even bypassing RNA extraction methods. 67 Importantly, the detected viral RNA levels were significantly above the infectivity threshold The COVID-19 pandemic caused by SARS-CoV-2 has resulted in excess morbidity and 73 mortality worldwide, especially in elderly populations and people with associated specific 74 comorbidities. [1] [2] [3] Adults and children above 12 years of age are being vaccinated at different 75 paces worldwide, 4 but younger children will remain more susceptible to infection. How new 76 variants will be transmitted amongst children and affect the community remains unclear. In 77 fact, thus far, the role of children in SARS-CoV-2 transmission remains poorly understood, 78 mostly because the majority of children with SARS-CoV-2 display mild to no symptoms; 5 it 79 has been estimated that 93% of infected children are not identified by symptom screening. 6 80 However, it is now well established that children are susceptible to infection, 7-9 and a small 81 percentage may develop serious complications, 10 including pneumonia, myocarditis, central 82 nervous system disorders, and multisystem inflammatory syndrome. 11, 12 It is critical in the 83 next phase of the pandemic, to have readily available strategies for minimally-invasive 84 approaches to monitor school settings; these strategies could help establish whether children 85 are prone to evolve new variants and how variants impact viral transmission by children to 86 the community by combining diagnosis with genotyping and epidemiological analyses. 87 Saliva molecular testing has emerged as a suitable alternative to nasopharyngeal (NP) swabs 88 for sampling and identification of SARS-CoV-2 RNA in children and adults, and for 89 genotyping SARS-CoV-2 variants. [13] [14] [15] Compared to NP swabs, saliva testing is less invasive 90 and may be implemented in self-collected or parent-assisted contexts more easily, including 6 under, admitted to hospital with COVID-19 related symptoms or with unrelated medical 97 pathologies or surgeries, and investigated the potential of saliva for being coupled to RT-PCR 98 testing, with saliva collected up to 48 h from a positive (or control) NP swab. Interestingly, 99 we found non-significant differences between methods using and bypassing RNA extraction. 100 In addition, we associated RNA levels detected in saliva with infectivity and quantified 101 specific SARS-CoV-2 spike and receptor-binding-domain (RBD) antibodies in this type of 102 sample. Interestingly, we only found statistically significant differences in IgM levels in 103 samples positive in swab-molecular testing that were negative by saliva-molecular testing, 104 suggesting that discrepancies between saliva and NP molecular tests are more frequent in 105 children infected for more than 7-10 days, which correlates to loss of infectivity and hence 106 transmission. Our study shows that saliva molecular testing bypassing RNA extraction is an 107 efficient method for monitoring SARS-CoV-2 infected children in age groups up to 10 years-108 old. 109 110 111 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 12, 2021. ; https://doi.org/10.1101/2021.08.11.21261899 doi: medRxiv preprint The ELISA assay used to quantify saliva IgG, IgA, and IgM anti-full-length SARS-CoV-2 187 spike and its receptor-binding domain (RBD) was adapted from 20 as described in 21, 22 , with 188 few modifications described here. Briefly, high binding 96 well plates (Maxisorb) were 189 coated with either RBD or spike as capture antigen at 0.5 µg/mL stored overnight at 4ºC. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 12, 2021. ; https://doi.org/10.1101/2021.08.11.21261899 doi: medRxiv preprint Method validation in adults 229 We first validated our method with adult patients admitted to Hospital Fernando Fonseca 230 with COVID-19, or without SARS-CoV-2 infection, as negative controls. Once SARS-CoV-231 2 infection was assessed by RT-qPCR on RNA extracted from a nasopharyngeal (NP) swab, 232 a saliva sample was collected within the following 48 hours. Saliva specimens were pre-233 treated with proteinase K, RNA was extracted and subjected to RT-qPCR using the primer 234 and probe sequences from the Center for Disease Control and Prevention. 24 Alternatively, 235 saliva samples treated with proteinase K were used directly for the RT-qPCR reaction, 236 without RNA extraction. 237 The overall concordances of saliva and NP swab were 98.0% (48/49) and 97.8% (46/47), 238 with and without RNA extraction from saliva, respectively (Table 1) (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 12, 2021. ; https://doi.org/10.1101/2021.08.11.21261899 doi: medRxiv preprint participants are shown in Table 2 . Forty-six (54.1%) were positive for SARS-CoV-2 infection 253 and, within these, 29 (63.0%) presented at least one COVID-19 symptom, the most common 254 being fever (50.0%), cough (28.0%), and coryza (28.0%). The remaining 17 children (37.0%) 255 were diagnosed on routine tests prior to hospital admission for causes non-related to COVID-256 19. Twenty-eight (32.9%) participants were under the age of 1 and the mean (SD) age was (Table 1) . Of the children with a positive NP swab, 84.8% were positive in saliva after 263 RNA extraction (39/46) and 81.1% (36/44) were positive in saliva without RNA extraction. 264 The specificity of the method was 100%, with the 39 patients negative by NP swab, also 265 negative in saliva, with and without RNA extraction. When restricting the analysis to children 266 younger than 1-year-old, the sensitivity of the method increases to 87.0% (25/28) with RNA 267 extraction and 86.4% (19/27) without RNA extraction from saliva (Table 1) . 268 The CT values in the saliva of children were significantly different from those in NP swab 269 (Figure 2A) , with a mean CT (SD) of 22.9 (6.2) in NP swab versus 26.1 (5.1) in saliva with 270 RNA extraction and 27.9 (4.7) without extraction. It is important to notice that there was a 271 time interval between NP swab and saliva collection that could go up to 48 h and, therefore, 272 these differences may not reflect a lower sensitivity of our method but rather a decrease in the 273 patient viral load. Importantly, there was no correlation between detection of SARS-CoV-2 in 274 saliva and the CT value of the NP swab, or the age of the patient ( Figure 2B ). 275 We also analyzed the stability of saliva samples from children when stored for 3 days at 4ºC 276 or 7 days at -20ºC prior to processing ( Figure 2C ). As for adults, saliva samples from children 277 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 12, 2021. ; https://doi.org/10.1101/2021.08.11.21261899 doi: medRxiv preprint were stable under the conditions tested, since viral RNA was detectable in all samples, 278 irrespective of whether RNA extraction was performed. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 12, 2021. ; https://doi.org/10.1101/2021.08.11.21261899 doi: medRxiv preprint IgAs (sIgAs) that recognize glycosylation patterns existent in spike. 25, 26 Only one (4.8%) 302 participant was positive for reactive IgM. 303 Of the 73 saliva samples from children tested by ELISA, 3 (3.1%) were positive for specific 304 IgG. Reactive IgA and IgM were detected in 44 (60.3%) and 5 (11.1%) participants, 305 respectively. Four participants with discrepant NP vs. saliva RT-qPCR data (NP positive, 306 saliva negative, n=12) presented IgM, suggesting that the corresponding samples were 307 collected after the first immune response, estimated to be 7-10 days post-infection, and 308 therefore after the peak of viral loads. 309 For children up to 10 years, IgG OD responses increased significantly (p<0.05) with age for 310 spike, while IgA OD responses to spike and RBD presented a marginally significant (p<0.1) 311 increase with age ( Figure 2F ). 312 313 314 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 12, 2021. ; https://doi.org/10.1101/2021.08.11.21261899 doi: medRxiv preprint The infection of SARS-CoV-2 in children remains under-diagnosed and poorly understood. 316 In particular, the role of children in viral transmission remains unclear, especially with the 317 emerging variants that increase viral transmission, such as the delta variant. In our work, we 318 corroborate findings that saliva molecular testing by methods similar to those described 319 previously 15 efficiently detects infected children, even in children unable to donate saliva 320 (Figure 2A) , for whom saliva was gently aspirated. Importantly, in children, the sensitivity, In addition, our study shows that SARS-CoV-2 infectious viruses may be rescued from saliva 338 samples with CTs lower than 26 ( Figure 2D, E) . Data suggest that high viral loads are prone 339 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 12, 2021. ; https://doi.org/10.1101/2021.08.11.21261899 doi: medRxiv preprint to result in viral transmission. 18 In our study, SARS-CoV-2 viral growth was not associated 340 with symptoms in children, but the sample size used was too low to draw conclusions 341 regarding how symptoms relate to viral loads. In fact, it has been shown that asymptomatic 342 children have significantly lower viral loads than symptomatic children. 7 Overall, it is well-343 established that infected children are more likely to remain asymptomatic or have milder 344 disease than adults; children are rarely hospitalized and rarely have fatal outcomes. 1 (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 12, 2021. ; https://doi.org/10.1101/2021.08.11.21261899 doi: medRxiv preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 12, 2021. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 12, 2021. ; https://doi.org/10.1101/2021.08.11.21261899 doi: medRxiv preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 12, 2021. ; https://doi.org/10.1101/2021.08.11.21261899 doi: medRxiv preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 12, 2021. ; https://doi.org/10.1101/2021.08.11.21261899 doi: medRxiv preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 12, 2021. ; https://doi.org/10.1101/2021.08.11.21261899 doi: medRxiv preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 12, 2021. ; https://doi.org/10.1101/2021.08.11.21261899 doi: medRxiv preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 12, 2021. ; https://doi.org/10.1101/2021.08.11.21261899 doi: medRxiv preprint Table 3 . Patients with antibodies in saliva against full-length spike or RBD, divided by age (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 12, 2021. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 12, 2021. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 12, 2021. ; https://doi.org/10.1101/2021.08.11.21261899 doi: medRxiv preprint Clinical Characteristics of Coronavirus Disease Prevalence of comorbidities and its effects in patients 391 infected with SARS-CoV-2: a systematic review and meta-analysis Clinical Characteristics of 138 Hospitalized Patients With 394 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China Should children get COVID vaccines? What the science says Estimating infectiousness throughout SARS-399 CoV-2 infection course Clinical Characteristics and Viral RNA Detection in 401 Children With Coronavirus Disease 2019 in the Republic of Korea SARS-CoV-2 viral RNA load dynamics in the 404 nasopharynx of infected children An analysis of SARS-CoV-2 viral load by 406 patient age SARS-CoV-2 Infection in Children Characteristics 413 of Children With Kawasaki Disease-Like Signs in COVID-19 Pandemic: A Systematic 414 Syndrome in Children (MIS-C) with COVID-19: Insights from simultaneous familial Kawasaki Disease cases Saliva Molecular Testing for SARS-CoV-419 Surveillance in Two Italian Primary Schools SARS-CoV-2 pandemic: a review of 421 molecular diagnostic tools including sample collection and commercial response with 422 associated advantages and limitations Saliva is more sensitive for SARS-424 CoV-2 detection in COVID-19 patients than nasopharyngeal swabs. medRxiv Limits and Opportunities of SARS-427 Antigen Rapid Tests: An Experienced-Based Perspective Saliva-Based Molecular Testing for SARS-429 CoV-2 that Bypasses RNA Extraction. bioRxiv